TimesSquare Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

TimesSquare Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-665,900	Closed	-$4.34M	–	204
2022 Q1	$4.34M	Buy	665,900 +6,800	+1%	+$50.8K	0.05%	189
2021 Q4	$7.68M	Buy	659,100 +8,500	+1%	+$128K	0.07%	189
2021 Q3	$12.1M	Sell	650,600 -32,800	-5%	-$623K	0.11%	195
2021 Q2	$14.5M	Buy	683,400 +286,200	+72%	+$6.6M	0.12%	189
2021 Q1	$8.06M	Sell	397,200 -27,200	-6%	-$736K	0.07%	196
2020 Q4	$11.3M	Buy	424,400 +6,700	+2%	+$144K	0.09%	200
2020 Q3	$9.36M	Buy	+417,700	New	+$9.83M	0.09%	203

Other funds holding TSHA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TCM

Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

TimesSquare Capital Management's TSHA Position: Q2 2022 in Review

TimesSquare Capital Management sold out of Taysha Gene Therapies (TSHA) in Q2 2022, closing a stake of 665,900 shares — an estimated $4.34M sold.

TimesSquare Capital Management first reported a position in TSHA in Q3 2020 and held it in 7 quarters. The position peaked at $14.5M in Q2 2021. 59 funds tracked by Wall St. Rank hold TSHA as of Q2 2022.

TimesSquare Capital Management reported no remaining Taysha Gene Therapies position as of Q2 2022 after selling out during the quarter.
TimesSquare Capital Management sold 665,900 Taysha Gene Therapies shares in Q2 2022, an estimated $4.34M.
TimesSquare Capital Management first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 7 quarters.
TimesSquare Capital Management's Taysha Gene Therapies position peaked at $14.5M in Q2 2021.
59 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2022.

Based on TimesSquare Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.